<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501149</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2011-2</org_study_id>
    <nct_id>NCT01501149</nct_id>
  </id_info>
  <brief_title>Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ</brief_title>
  <acronym>CTTNKTL-Ⅲ/Ⅳ</acronym>
  <official_title>A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan TongJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of DDGP regiment
      (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer
      (NK)/T Cell Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be
      treated successfully with the conventional chemotherapy of CHOP. The investigators have been
      proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy
      regiment DDGP (gemcitabine，pegaspargase, cisplatin, dexamethasone) in the patients with stage
      Ⅲ/Ⅳ NK/T cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )</time_frame>
    <description>21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasal and Nasal-type NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>DDGP regiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMILE Regiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)</intervention_name>
    <description>DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>DDGP regiment</arm_group_label>
    <other_name>DDGP regiment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）</intervention_name>
    <description>MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>SMILE Regiment</arm_group_label>
    <other_name>Modified SMILE regiment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3
             months

          -  Histological confirmed NK/T cell lymphoma

          -  None of chemotherapy or radiotherapy has been previously used

          -  None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L,
             platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤
             1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is
             normal (Inclusion Criteria of 1,3,6 groups )

          -  At least one measurable lesion

          -  None of other serious diseases, cardiopulmonary function is normal

          -  Pregnancy test of women at reproductive age must be negative

          -  Patients could be followed up

          -  None of other relative treatments including the traditional Chinese medicine,
             immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic
             treatments.

          -  volunteers who signed informed consent.

        Exclusion Criteria:

          -  Disagreement on blood sample collection

          -  Patients allergic of any of drug in this regimen or with metabolic disorder

          -  Pregnant or lactating women

          -  Serious medical illness likely to interfere with participation

          -  Serious infection

          -  Primitive or secondary tumors of central nervous system

          -  Chemotherapy or radiotherapy contraindication

          -  The evidence of CNS metastasis

          -  History of peripheral nervous disorder or dysphrenia

          -  patients participating in other clinical trials

          -  patients taking other antitumor drugs

          -  patients estimated to be unsuitable by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro，Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>mingzhi_zhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <email>mingzhi_zhang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <investigator>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>NK/T cell lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>clinical trial</keyword>
  <keyword>RR</keyword>
  <keyword>PFS</keyword>
  <keyword>OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

